JP4238031B2 - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP4238031B2
JP4238031B2 JP2002570736A JP2002570736A JP4238031B2 JP 4238031 B2 JP4238031 B2 JP 4238031B2 JP 2002570736 A JP2002570736 A JP 2002570736A JP 2002570736 A JP2002570736 A JP 2002570736A JP 4238031 B2 JP4238031 B2 JP 4238031B2
Authority
JP
Japan
Prior art keywords
mouse
protein
cil
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002570736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502314A5 (https=
JP2005502314A (ja
Inventor
アシュマン，クレア
クロウ，ジェームズ，スコット
エリス，ジョナサン，ヘンリー
ルイス，アラン，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005502314A publication Critical patent/JP2005502314A/ja
Publication of JP2005502314A5 publication Critical patent/JP2005502314A5/ja
Application granted granted Critical
Publication of JP4238031B2 publication Critical patent/JP4238031B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002570736A 2001-03-03 2002-03-01 ワクチン Expired - Fee Related JP4238031B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine

Publications (3)

Publication Number Publication Date
JP2005502314A JP2005502314A (ja) 2005-01-27
JP2005502314A5 JP2005502314A5 (https=) 2005-12-22
JP4238031B2 true JP4238031B2 (ja) 2009-03-11

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002570736A Expired - Fee Related JP4238031B2 (ja) 2001-03-03 2002-03-01 ワクチン

Country Status (18)

Country Link
US (3) US20050260216A1 (https=)
EP (1) EP1368477A1 (https=)
JP (1) JP4238031B2 (https=)
KR (1) KR20030081490A (https=)
CN (1) CN1543504A (https=)
AU (1) AU2002233560B2 (https=)
BR (1) BR0207819A (https=)
CA (1) CA2439628A1 (https=)
CZ (1) CZ20032373A3 (https=)
GB (1) GB0105360D0 (https=)
HU (1) HUP0303372A3 (https=)
IL (1) IL157498A0 (https=)
MX (1) MXPA03007915A (https=)
NO (1) NO20033882L (https=)
NZ (1) NZ527873A (https=)
PL (1) PL365066A1 (https=)
WO (1) WO2002070711A1 (https=)
ZA (1) ZA200306647B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287400B6 (sk) * 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
JP2006503017A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
EP1539232A1 (en) * 2002-09-12 2005-06-15 Pharmexa A/S Immunization against autologous ghrelin
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
CA2514979A1 (en) * 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
EP1608316A4 (en) * 2003-03-24 2007-08-15 Mercia Pharma Inc METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY CONDITIONS
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
ES2389080T3 (es) * 2004-06-11 2012-10-23 Riken Fármaco que presenta un ligando de células reguladoras contenido en el liposoma
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
BRPI0810561A2 (pt) * 2007-04-23 2019-09-24 Wyeth Corp métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
NZ599777A (en) * 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN117222664A (zh) * 2021-01-29 2023-12-12 拜耳动物保健有限责任公司 用于破坏自身耐受的疫苗组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
ATE509102T1 (de) * 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
JPH10503371A (ja) * 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
CA2213301C (en) * 1995-02-20 2010-01-26 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
CA2322624A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Induction of immunity against tumor self-antigens
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
AU5617900A (en) * 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
CA2404763A1 (en) * 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
HUP0303372A3 (en) 2008-06-30
US20050260216A1 (en) 2005-11-24
EP1368477A1 (en) 2003-12-10
ZA200306647B (en) 2004-11-26
NO20033882D0 (no) 2003-09-02
CZ20032373A3 (cs) 2004-01-14
CN1543504A (zh) 2004-11-03
WO2002070711A1 (en) 2002-09-12
US20030194391A1 (en) 2003-10-16
PL365066A1 (en) 2004-12-27
NZ527873A (en) 2005-12-23
BR0207819A (pt) 2004-03-02
CA2439628A1 (en) 2002-09-12
IL157498A0 (en) 2004-03-28
AU2002233560B2 (en) 2006-09-07
GB0105360D0 (en) 2001-04-18
NO20033882L (no) 2003-10-31
HUP0303372A2 (hu) 2004-01-28
JP2005502314A (ja) 2005-01-27
KR20030081490A (ko) 2003-10-17
MXPA03007915A (es) 2003-12-04
US20050186209A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
JP4238031B2 (ja) ワクチン
AU2002233560A1 (en) Vaccine
KR100671036B1 (ko) 오스테오프로테게린 리간드 활성을 하향-조절하는 방법
ES2527410T3 (es) Inmunoconjugados de miostatina para el tratamiento de atrofia muscular progresiva
JP6987744B2 (ja) 虫刺され過敏症の治療
CZ9903657A3 (cs) Modifikované molekuly TNFalfa, DNA kódující takové modifikované molekuly TNFalfa a vakcíny obsahující uvedené modifikované molekuly TNFalfa
KR19990022654A (ko) 보호 면역 반응을 증강시키는 방법
JP2022513452A (ja) 融合によって修飾されたｃｍｖのウイルス様粒子
US20060147417A1 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
KR20020084841A (ko) Ｉｌ5 활성을 다운-조절하는 방법
KR101101004B1 (ko) 신규한 펩티드 및 그들의 치료 용도
JP2019515957A (ja) イヌアトピー性皮膚炎の治療
JP2006503018A (ja) ワクチン
CA2421274A1 (en) Method for down-regulating ige
US20130122026A1 (en) Dna vaccine for alzheimer's disease
US20010044418A1 (en) Treatment of allergies
JP2005529091A (ja) エオタキシン伝達炎症状態の処置および予防方法および組成物
CN121532207A (zh) 用于治疗特应性皮炎的主动免疫
KR20060010730A (ko) 염증 상태를 치료하고 예방하기 위한 방법과 조성물
JP2002516875A (ja) 動物の繁殖行動を抑制する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081219

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111226

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees